On June 3, 2022, a stakeholders’ meeting to validate the assumptions of the “Cost-effectiveness HVP vaccine in Burkina Faso” model was held in the conference room of the Ministry of Health’s Information Services Department.

The specific objectives of the meeting were :

  • Present the economic evaluation and disease modelling methods.
  • Inform stakeholders of the rationale and proposed methods for assessing the cost-effectiveness of HPV in Burkina Faso
  • Obtain stakeholder feedback on a proposed set of model input parameters, assumptions and uncertainty analyses.
  • Agree on next steps and a proposed date for a dissemination/final results workshop

The meeting was chaired by the Direction de la Prévention par la Vaccination (DPV). Its objective was to validate the model’s hypotheses in the basic scenario of the cost-effectiveness study of the introduction of the HPV vaccine in Burkina Faso.

The representative of the VPD first welcomed the 11 participants. After the welcoming address, Dr Annick SIDIBE presented the context of the study, the overall structure of the project, the main methods used in the study and the UNIVAC model used to estimate the parameters. The participants, especially those from the DPV, helped to confirm some of the values introduced in the UNIVAC model.

Dr Jöel Arthur KIENDREBEOGO then presented the approaches to economic evaluation and disease modelling (reference to the WHO Guidelines) and particularly the cost-effectiveness model that was used and clarified the assumptions that were used in the study. All the presentations lasted about 1h 30 min and helped the participants to understand the study.

At the end of the presentations, the participants asked questions to understand some aspects of the study. These included questions about the target population of the study, whether the investigators had the proportion of girls exposed to HPV in Burkina Faso. Whether the study paid enough attention to not under- or over-estimating the target population. To this question, the study investigators said in reply that the study used DALYs and only estimated the HPV burden. The prevalence of HPV in the target population was not necessary.

Overall, the participants had a very good understanding of the study and really appreciated the approach that was used. Finally, they expressed their availability and support for the success of the study.